Latest News

New Drug Approved by FDA for Treatment of Seizures Associated with Dravet Syndrome
Officials with the FDA have approved stiripentol (Diacomit) for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy.
Pembrolizumab in combination with chemotherapy reduced the risk of death by half in patients with metastatic, non-squamous non-small cell lung cancer compared with chemotherapy alone.
An expert panel of health care providers and patients are recommending that opioid prescribing limits should be based on the operation performed rather than a blanket approach.
Understanding specialty drug pricing, and the flow of health care dollars through the lens of the stakeholders involved.
Interventions must address HIV testing and beliefs among both patients and providers in order to reach underserved populations.
The use of benzodiazepines and related z-drugs was found to be associated with a modest increase in the risk of Alzheimer disease in a case-control trial.
Top news of the day from across the health care landscape.
Study evaluates the effect of multiple sclerosis treatment alemtuzumab (Lemtrada) on the B-cell component of MS.


A Case for Biosimilar Use: 5 Things You Need to Know
Biosimilars are a potential solution to the ever-growing problem of high specialty drug costs.
Specialty infusion pharmacy should be thought of in terms of superlatives, such as most complex and highest cost.
Approximately 80% of manufacturers are already managing their products, many of which are oncology drugs, through a limited distribution model.
The meteoric rise in drug spending over the past 10 years has been driven by specialty therapeutics, while spending on traditional therapies has decreased.

Featured Company Profile

MHA Specialty Pharmacy Solutions: Patient Engagement Strategies for Your Pharmacy


Achilles Alon, PharmD, RPh, director of Specialty Pharmacy, co-owner of ACE-Rx Specialty Pharmacy, discusses biosimilars and the potential impact on patient care.

A look at last week's top stories in the world of pharmacy.

Jesse C. Dresser, JD, Partner, Frier & Levitt, LLC, speaks about the regulation of pharmacy benefit managers and how it can impact specialty pharmacy operations.

Current Issue

Volume: 9
Number: 5

Most Popular

Previous TabNext Tab
Strategic Alliance Partners
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.